Sensei finds Faeth
The company buys in a PI3Kα and mTOR combo.
MAT2A inhibition gets another endorsement
Gilead opting against IDE397 is still good news for Ideaya.
Cardiff goes south again
The latest onvansertib data, and an abrupt CEO departure, spook investors.
Novartis perseveres with pelabresib
A new phase 3, Manifest-3, will start in April to support US filing.
Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
Pfizer trims its pan-KRAS efforts
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
